CLINICAL TRIALS PROFILE FOR ELIGARD
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Eligard
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00005044 ↗ | Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | Unknown status | National Cancer Institute (NCI) | Phase 3 | 2000-02-01 | RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer. |
| NCT00005044 ↗ | Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | Unknown status | Radiation Therapy Oncology Group | Phase 3 | 2000-02-01 | RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer. |
| NCT00170157 ↗ | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | Completed | Medarex | Phase 2 | 2004-06-01 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer. |
| NCT00170157 ↗ | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2004-06-01 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer. |
| NCT00170157 ↗ | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | Completed | U.S. Army Medical Research Acquisition Activity | Phase 2 | 2004-06-01 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer. |
| NCT00170157 ↗ | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | Completed | United States Department of Defense | Phase 2 | 2004-06-01 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer. |
| NCT00170157 ↗ | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | Completed | Mayo Clinic | Phase 2 | 2004-06-01 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Eligard
Condition Name
Clinical Trial Locations for Eligard
Trials by Country
Clinical Trial Progress for Eligard
Clinical Trial Phase
Clinical Trial Sponsors for Eligard
Sponsor Name
